Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2146966
Max Phase: Preclinical
Molecular Formula: C62H98N14O10
Molecular Weight: 1199.55
Molecule Type: Protein
Associated Items:
ID: ALA2146966
Max Phase: Preclinical
Molecular Formula: C62H98N14O10
Molecular Weight: 1199.55
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC(C)(C)C[C@@H]1NC(=O)[C@H](CCCN)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCCN)NC(=O)[C@H](CC(C)(C)C)NC(=O)[C@H](CCCN)NC(=O)[C@@H]2CCCN2C(=O)[C@@H](Cc2ccccc2)NC(=O)[C@H](CCCN)NC1=O
Standard InChI: InChI=1S/C62H98N14O10/c1-61(2,3)37-47-55(81)67-41(23-13-29-63)51(77)71-45(35-39-19-9-7-10-20-39)59(85)76-34-18-28-50(76)58(84)70-44(26-16-32-66)54(80)74-48(38-62(4,5)6)56(82)68-42(24-14-30-64)52(78)72-46(36-40-21-11-8-12-22-40)60(86)75-33-17-27-49(75)57(83)69-43(25-15-31-65)53(79)73-47/h7-12,19-22,41-50H,13-18,23-38,63-66H2,1-6H3,(H,67,81)(H,68,82)(H,69,83)(H,70,84)(H,71,77)(H,72,78)(H,73,79)(H,74,80)/t41-,42-,43-,44-,45+,46+,47-,48-,49-,50-/m0/s1
Standard InChI Key: HLAPMLZLLMPSCE-XNNAEKOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1199.55 | Molecular Weight (Monoisotopic): 1198.7590 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Kapoerchan VV, Knijnenburg AD, Keizer P, Spalburg E, de Neeling AJ, Mars-Groenendijk RH, Noort D, Otero JM, Llamas-Saiz AL, van Raaij MJ, van der Marel GA, Overkleeft HS, Overhand M.. (2012) 'Inverted' analogs of the antibiotic gramicidin S with an improved biological profile., 20 (20): [PMID:22989907] [10.1016/j.bmc.2012.08.038] |
Source(1):